Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 943 across all filing types
Latest filing 2026-05-12 Earnings Release
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release under Regulation 30 announcing the company’s financial results for Q4 and year ended March 31, 2026, providing summary metrics (total income, EBITDA, profit after tax) and CEO comments, followed by an earnings call invite. It is not the full quarterly report but an initial public earnings release of key highlights. Therefore, it fits the Earnings Release category. FY 2026
2026-05-12 English
Dividend
Regulatory Filings Classification · 85% confidence The document is clearly a statutory board meeting outcome notice filed under SEBI Listing Regulations (Reg. 30 & 33), announcing the approval of audited annual financial results, recommendation of final dividend, appointment of an additional director, AGM date and record date, and capacity enhancement. It also includes the full Independent Auditor’s Report as an attachment. This is a regulatory stock‐exchange filing combining multiple board decisions rather than a standalone annual report, earnings release, or detailed MD&A. It therefore best fits the “Regulatory Filings” category (RNS) as a general regulatory announcement.
2026-05-12 English
Audited Financial Results and recommendation of final dividend for financial year 2025-26
Regulatory Filings Classification · 85% confidence The document is an outcome of a Board meeting submitted to BSE/NSE under SEBI Listing Regulations 30 & 33. It discloses and encloses the audited standalone & consolidated financial results for the year ended March 31, 2026 (along with the Statutory Auditor’s report), plus corporate actions such as dividend recommendation, director appointment, AGM date, record date and capacity expansion details. This is not a full Annual Report (10-K), nor solely an Audit Report (AR), nor just a timing notice (RPA). It is a regulatory disclosure of board-approved results and related information. Accordingly, it falls under the general Regulatory Filings category (RNS).
2026-05-12 English
Outcome of Board Meeting
Regulatory Filings Classification · 90% confidence The document is a formal letter from Neuland Laboratories to the BSE and NSE under SEBI Listing Regulations 30 and 33 detailing the outcome of a Board meeting. It includes the audited annual financial results for the year ended March 31, 2026, the statutory auditor’s report, a dividend recommendation, a director appointment, AGM details, and capacity expansion information. This is a regulatory announcement of the board’s resolutions and financial results, not a full Annual Report (10-K), Interim Report (IR), or other stand-alone category like an earnings call transcript. It is a compliance filing disclosing results and corporate actions pursuant to stock exchange regulations, fitting the “Regulatory Filings” fallback category (RNS).
2026-05-12 English
Audited Financial Results and recommendation of final dividend for financial year 2025-26
Audit Report / Information Classification · 90% confidence The document is a formal regulatory filing under SEBI LODR summarizing the outcome of a board meeting, including the approval of Audited Financial Results for the year ended March 31, 2026, and it encloses the full statutory auditor’s report with unmodified opinion. This is not the full annual report (10-K) or a mere earnings highlights release (ER), nor is it just an announcement of publication (RPA). It constitutes a standalone audit report on the consolidated annual financial results, fitting the definition of Audit Report / Information (AR). FY 2026
2026-05-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about the schedule of an earnings call for the fourth quarter and full year ended March 31, 2026. It references the upcoming announcement of financial results and provides details for the earnings call event. The document does not contain actual financial results or detailed financial data but serves as an intimation or announcement of the earnings call. Therefore, it is not the earnings release itself but an announcement related to the earnings call. According to the filing definitions, this type of document is best classified as a Call Transcript (CT) if it contained the transcript, but since it only announces the call schedule, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call schedule without substantive financial data or transcript content. The document length is short (2731 characters), supporting that it is an announcement rather than a full report or transcript.
2026-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.